Zileuton induces hemoglobin F synthesis in erythroid progenitors: role of the L-arginine-nitric oxide signaling pathway.

Induction of fetal hemoglobin (Hb F) is an important therapeutic tool in ameliorating complications of sickle cell disease. Nitric oxide has been implicated in the mechanism of Hb F synthesis induced by hydroxyurea (HU). This study examined whether zileuton (ZL), a structural analog of hydroxyurea, possessed Hb F-inducing properties and the potential role nitric oxide plays. ZL caused a dose-dependent increase in gamma-globin expression in K562 cells. This effect was confirmed by a dose-dependent increase in Hb F synthesis in erythroid progenitors from individuals with sickle cell anemia and normal hemoglobin genotypes. l-arginine had no effect on Hb F production; however, it dose-dependently inhibited ZL's ability to induce Hb F. The nitric oxide synthase inhibitor N(G)-monomethyl-l-arginine (l-NMMA) inhibited l-arginine's effect and restored ZL-mediated increase in Hb F synthesis. In addition, 8-PCPT-cGMP (8-(4-chlorophenylthio)guanosine 3',5'-cyclic monophosphate) inhibited ZL-mediated induction of Hb F synthesis. When comparing l-NMMA effects alone on ZL and HU, a partial reversal of increased Hb F synthesis was seen only with HU. Neither l-arginine alone nor l-arginine in combination with l-NMMA effected hydroxyurea-mediated induction of Hb F synthesis. This study demonstrates that ZL induces Hb F through a mechanism that involves l-arginine/nitric oxide/cGMP in a manner distinctly different from HU.

[1]  C. Pegelow,et al.  Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. , 2003, JAMA.

[2]  M. Gladwin,et al.  Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase. , 2003, The Journal of clinical investigation.

[3]  M. Cappellini,et al.  Mechanism for fetal globin gene expression: role of the soluble guanylate cyclase-cGMP-dependent protein kinase pathway. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Perlingeiro,et al.  HYDROXYUREA PROMOTES THE REDUCTION OF SPONTANEOUS BFU-e TO NORMAL LEVELS IN SS AND S/β THALASSEMIC PATIENTS , 2001, Hemoglobin.

[5]  B. Pace,et al.  Mechanism for fetal hemoglobin induction by hydroxyurea in sickle cell erythroid progenitors , 2000, American journal of hematology.

[6]  P. V. Ichinsky,et al.  Causes and Outcomes of the Acute Chest Syndrome in Sickle Cell Disease , 2000 .

[7]  E. Bleecker,et al.  Anti-inflammatory effects of zileuton in a subpopulation of allergic asthmatics. , 2000, American journal of respiratory and critical care medicine.

[8]  J. Drazen.  Clinical pharmacology of leukotriene receptor antagonists and 5-lipoxygenase inhibitors. , 1998, American journal of respiratory and critical care medicine.

[9]  J. Barberà,et al.  The effects of 5-lipoxygenase inhibition by zileuton on platelet-activating-factor-induced pulmonary abnormalities in mild asthma. , 1998, American journal of respiratory and critical care medicine.

[10]  S. Ballas,et al.  Time resolved absorption study of the reaction of hydroxyurea with sickle cell hemoglobin. , 1998, Biochimica et biophysica acta.

[11]  B. Pace,et al.  BFU‐E colony growth in response to hydroxyurea: Correlation between in vitro and in vivo fetal hemoglobin induction , 1997 .

[12]  B. Pace,et al.  Globin Gene Silencing in Primary Erythroid Cultures , 1997, The Journal of Biological Chemistry.

[13]  M L Terrin,et al.  Hydroxyurea and Sickle Cell Anemia Clinical Utility of a Myelosuppressive “Switching” Agent , 1996, Medicine.

[14]  F. Murad.  Signal Transduction Using Nitric Oxide and Cyclic Guanosine Monophosphate , 1996 .

[15]  D. Wink,et al.  Hydroxyurea reacts with heme proteins to generate nitric oxide , 1996, The Lancet.

[16]  P. Boyle,et al.  Testicular-cancer incidence and mortality in Slovakia, 1968-90 , 1996, The Lancet.

[17]  S. Wenzel,et al.  Effect of 5-lipoxygenase inhibition on bronchoconstriction and airway inflammation in nocturnal asthma. , 1995, American journal of respiratory and critical care medicine.

[18]  M L Terrin,et al.  Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. , 1995, The New England journal of medicine.

[19]  K. Hackshaw,et al.  A pilot study of zileuton, a novel selective 5-lipoxygenase inhibitor, in patients with systemic lupus erythematosus. , 1995, The Journal of rheumatology.

[20]  J. Bouska,et al.  Optimization of the potency and duration of action of N-hydroxyurea 5-lipoxygenase inhibitors. , 1995, The Journal of pharmacology and experimental therapeutics.

[21]  O. Platt,et al.  Mortality in sickle cell disease. Life expectancy and risk factors for early death. , 1994, The New England journal of medicine.

[22]  M. Nakatsuka,et al.  Selective inhibition of the 12-lipoxygenase pathway of arachidonic acid metabolism by L-arginine or sodium nitroprusside in intact human platelets. , 1994, Biochemical and biophysical research communications.

[23]  B. Pace,et al.  Transgenic mouse model of pharmacologic induction of fetal hemoglobin: Studies using a new ribonucleotide reductase inhibitor, didox , 1994, American journal of hematology.

[24]  U. Walter,et al.  The nitric oxide and cGMP signal transduction system: regulation and mechanism of action. , 1993, Biochimica et biophysica acta.

[25]  K. Ivanova,et al.  Influence of the cGMP analog 8-PCPT-cGMP on agonist-induced increases in cytosolic ionized Ca2+ and on aggregation of human platelets. , 1993, European journal of pharmacology.

[26]  D. Faller,et al.  A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. , 1993, The New England journal of medicine.

[27]  J. Kremer,et al.  Zileuton, a 5-lipoxygenase inhibitor in rheumatoid arthritis. , 1992, The Journal of rheumatology.

[28]  P. Young,et al.  The discovery and development of zileuton: an orally active 5-lipoxygenase inhibitor. , 1992, International journal of immunopharmacology.

[29]  R. D. Dyer,et al.  5-lipoxygenase inhibitory activity of zileuton. , 1991, The Journal of pharmacology and experimental therapeutics.

[30]  K. Stolze,et al.  EPR studies on the oxidation of hydroxyurea to paramagnetic compounds by oxyhemoglobin. , 1990, Biochemical pharmacology.

[31]  G. Stamatoyannopoulos,et al.  Stimulation of fetal hemoglobin synthesis by erythropoietin in baboons. , 1987, The New England journal of medicine.

[32]  T. Ley,et al.  5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. , 1982, The New England journal of medicine.

[33]  L. Dubé,et al.  Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma , 1999, Clinical reviews in allergy & immunology.

[34]  L. Dubé,et al.  ZILEUTON : THE FIRST LEUKOTRIENE SYNTHESIS INHIBITOR FOR USE IN THE MANAGEMENT OF CHRONIC ASTHMA , 1998 .

[35]  T. Reiss,et al.  Montelukast—An Antileukotriene Treatment for Asthma: Changing the Asthma-Treatment Paradigm , 1998 .

[36]  5—Azacytidine selectively increases globin synthesis in a patient with thalassemia , 1983 .

[37]  M. Horsmanheimo,et al.  Lung biology in health and disease , 1977 .